Compare L3Harris Technologies Inc (LHX) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
L3Harris Technologies Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? L3Harris Technologies Inc trades at $239.22 (market cap $43.71B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: L3Harris Technologies Inc is far larger — about 9× Travere Therapeutics Inc. Common Stock's market cap, and L3Harris Technologies Inc pays a 2.13% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold L3Harris Technologies Inc for 56 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| LHX | TVTX | |
|---|---|---|
Market Cap | $43.71B | $4.88B |
Volume | 1,558,148 | 1,668,577 |
Sector | Industrials | Health |
52-Week High | $378.48 | $67.52 |
52-Week Low | $233.63 | $26.79 |
Typical Hold Time | 56 Days | 0 Days |
Enterprise Value | $54.15B | $5.01B |
Dividend Yield | 2.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LHX trades at $237.50, down 0.31% with a bearish technical signal. The company shows solid fundamentals with consistent earnings beats, revenue growth from $21.3B to $21.9B (2024-2025), and a net income margin improving to 7.34%. Recent news includes a $6B THAAD propulsion contract but also multiple law firm investigations into investor claims, creating mixed sentiment.
Outlook: Strong defense budget tailwinds and recent contract wins support growth, but legal scrutiny and bearish technicals pose near-term risks. Analyst consensus is bullish with a $340 price target (43% upside), highlighting value if legal concerns resolve favorably.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
